THCA

The main cannabinoid receptor in the brain, responsible for THC’s intoxicating effects. Direct same-assay research found that Delta-9-THC binds CB1 approximately 62x more strongly than THCA, although reported THCA affinity varies substantially between studies. THCA also shows only weak direct CB1 activation and has been classified as a partial agonist in functional testing.

THCA can also act as a positive allosteric modulator of CB1, meaning it can strengthen receptor activation produced by another CB1 agonist without relying only on direct activation itself. This suggests that THCA can influence CB1 signalling in more than one way, despite its relatively weak direct activity.

THCA also enters the brain very poorly compared with Delta-9-THC, which further limits central CB1 activation and helps explain why unheated THCA produces little to no THC-like intoxication. When THCA is heated and converted into Delta-9-THC, the resulting psychoactive effects are driven mainly by Delta-9-THC instead.

The main cannabinoid receptor in the immune system, involved in regulating immune cell activity and inflammatory responses. THCA shows very weak direct CB2 agonist activity, and some functional studies instead found antagonist or inverse-agonist-like behaviour, meaning THCA may reduce CB2 signalling rather than activate it.

PPARγ is a receptor inside cells that regulates genes involved in inflammation, metabolism and cell protection. THCA binds PPARγ with a Ki of approximately 209 nM and acts as a partial agonist, activating the receptor more strongly than Delta-9-THC.

In animal models of Huntington’s disease, THCA activation of PPARγ reduced inflammation and nerve cell damage and improved movement. These protective effects were strongly reduced when PPARγ was blocked, confirming that this receptor directly contributed to the effects.

Unlike CB1, PPARγ works relatively slowly by changing which genes a cell uses. This can gradually alter the proteins produced by the cell and could contribute to longer lasting anti inflammatory, metabolic and neuroprotective effects, although these effects have not yet been confirmed in humans.

TRP channels are ion channels involved in pain, temperature and sensory signalling. THCA directly interacts with several of these channels, particularly TRPA1, TRPM8, TRPV2 and TRPV1.

THCA activates TRPA1, a channel involved in detecting irritating stimuli, temperature changes and pain signals. Activation followed by reduced responsiveness could contribute to reduced pain signalling over time.

THCA strongly inhibits TRPM8, with an IC50 of approximately 0.15 µM, similar to Delta-9-THC in the same assay. TRPM8 is involved in sensing cold temperatures, so reducing its activity could decrease cold related sensory and pain signalling.

THCA also activates TRPV2, although considerably more weakly than Delta-9-THC. TRPV2 contributes to pain and other cellular signalling, so its activation could influence pain related and sensory responses.

At TRPV1, THCA shows little direct activation but can reduce the channel’s response to capsaicin at higher concentrations. This could reduce heat and pain related signalling, although the effect is considerably weaker than THCA’s activity at TRPM8 and TRPA1.

These TRP interactions are established in laboratory research, but their contribution to THCA’s effects in humans remains uncertain.

T-type calcium channels help control how easily nerve cells become electrically active and are involved in pain and seizure-related signalling. THCA directly inhibits the human CaV3.1, CaV3.2 and CaV3.3 channels, reducing the amount of calcium that can enter through them.

THCA showed its strongest effect at CaV3.1, where higher concentrations produced almost complete inhibition. At CaV3.2, THCA reduced channel activity by approximately 53%, while CaV3.3 activity was reduced by approximately 43% at the same tested concentration.

By reducing T-type calcium channel activity, THCA could make certain nerve cells less easily activated, potentially contributing to pain-reducing and seizure-related effects. These interactions are directly established in human receptor systems, but their contribution to THCA’s specific effects in humans has not yet been confirmed.

DAGLα is an enzyme that produces 2-AG, one of the body’s main endocannabinoids. 2-AG normally activates CB1 and CB2 receptors and helps regulate pain, mood, appetite and other nervous-system functions.

THCA directly inhibits DAGLα. This could reduce the production of 2-AG and therefore decrease some natural CB1 and CB2 signalling. This interaction is directly established in laboratory research, but it requires relatively high THCA concentrations, so its importance to THCA’s effects in humans remains uncertain.

Animal research shows that THCA undergoes hydroxylation and further oxidation, producing metabolites including 11-OH-THCA and THCA-COOH, together with several other oxidized metabolites. The body then further processes these metabolites so they can be eliminated.

The pharmacological activity of 11-OH-THCA and other THCA metabolites remains largely unknown.